About
Radiopharmaceutical labeling
Areas of Focus
Categories
Small Molecule PharmaceuticalRadiopharmaceuticalsAustralia
Clinical Trials (14)
View allTotal Trials
14
As Lead Sponsor
11
As Collaborator
3
Total Enrollment
1,107
By Phase
PHASE3: 2PHASE2: 4PHASE1/PHASE2: 6PHASE1: 1EARLY_PHASE1: 1
By Status
COMPLETED: 7RECRUITING: 4TERMINATED: 2UNKNOWN: 1
Clinical Trials Pipeline14 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06970847Lead Sponsor
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
PHASE3Recruiting
220 participants
Started: May 16, 2025 · Completed: Dec 31, 2026
NCT06907641Collaborator
Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy
PHASE2Recruiting
50 participants
Started: Nov 21, 2024 · Completed: Nov 30, 2025
NCT06056830Lead Sponsor
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
PHASE3Recruiting
383 participants
Started: Dec 21, 2023 · Completed: Dec 31, 2025
NCT05633160Lead Sponsor
64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)
PHASE1/PHASE2Terminated
4 participants
Started: Jun 15, 2023 · Completed: Apr 23, 2025
NCT05407311Lead Sponsor
64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
PHASE2Completed
53 participants
Started: Sep 19, 2022 · Completed: May 13, 2024
Locations (1)
Headquarters
Eveleigh, Australia
Map
Loading map...